Molecular Templates, Inc.

About

Creating Novel Therapies for Cancer and Other Serious Diseases

Molecular Templates is developing novel therapies in oncology and other serious diseases through its proprietary biologic engineered toxin body (ETB) drug platform. ETBs are targeted, can induce their own internalization, and can destroy cells through novel mechanisms of action.

Technology That Sets Us Apart

Our ETBs:

  • Offer a new modality against clinically established targets;
  • Force internalization of poorly or non-internalizing target receptors;
  • Possess a potent and novel mechanism of action to destroy cells;
  • Deliver payloads including antigen seeding technology; and
  • Employ a proprietary de-immunized toxin scaffold to reduce adaptive and innate response.
View Technology

Our Developing Pipeline Addresses Multiple Indications

Molecular Templates has multiple compounds in the clinic.

View Pipeline

MT-3724

MT-3724 is a 1st generation ETB that utilizes wild-type Shiga-like toxin A (SLTA) genetically fused to an scFv to CD20 designed to bind, induce internalization, and destroy CD20-expressing tumor cells through ribosomal inactivation.

View Candidate

MT-5111

MT-5111 is a 2nd generation ETB technology that utilizes a genetically engineered de-immunized Shiga-like toxin A-subunit (SLTA) designed to reduce the potential for innate and adaptive immunogenicity. MT-5111 was designed to directly kill HER2-positive cells via ribosomal inactivation, a differentiated mechanism from approved HER2 targeted agents.

View Candidate

TAK-169

TAK-169 is a 2nd generation ETB that utilizes a genetically engineered de-immunized Shiga-like toxin A-subunit (SLTA) designed to reduce the potential for innate and adaptive immunogenicity. TAK-169 targets CD38, a poorly internalizing receptor expressed on myeloma cells. TAK-169 was designed to directly kill CD38-expressing tumor cells via ribosomal inactivation.

View Candidate

Continuing Discovery Through Partnerships

Molecular Templates continues to gain external validation of the ETB platform through discovery and clinical-stage collaborations with pharma. The company‚Äôs collaboration with Takeda Pharmaceuticals is focused on the development of novel and differentiated oncology therapeutics.  The partnership with Vertex Pharmaceuticals reflects utility of the platform outside of oncology.

View Partnerships

Leaders with Experience and Passion

The Molecular Templates leadership team has a track record of success in biotechnology and pharmaceuticals. We are driven to improve outcomes for cancer patients.